Wayne J G Hellstrom

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7796068/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hematospermia Etiology, Diagnosis, Treatment, and Sexual Ramifications: A Narrative Review. Sexual Medicine Reviews, 2022, 10, 669-680.	2.9	3
2	Medicolegal Impacts of Penile Implant Surgery. , 2022, , 247-258.		0
3	Considerations on Inflatable Penile Prosthesis Reservoir Placement. , 2022, , 79-96.		Ο
4	Safety of penile prosthesis surgery in solid organ transplant patients. International Journal of Impotence Research, 2022, 34, 507-508.	1.8	1
5	Revelations on Men Who Seek Penile Augmentation Surgery: A Review. Sexual Medicine Reviews, 2022, 10, 460-467.	2.9	6
6	MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases. Advances in Therapy, 2022, 39, 3403-3422.	2.9	26
7	Does Lowering Hemoglobin A1c Reduce Penile Prosthesis Infection: A Systematic Review. Sexual Medicine Reviews, 2021, 9, 628-635.	2.9	10
8	A Systematic Review of Penile Prosthesis Surgery in Organ Transplant Recipients. Sexual Medicine Reviews, 2021, 9, 636-640.	2.9	5
9	Application of Botulinum Neurotoxin in Female Sexual and Genitourinary Dysfunction: A Review of Current Practices. Sexual Medicine Reviews, 2021, 9, 57-63.	2.9	8
10	Review of Intralesional Collagenase Clostridium Histolyticum Injection Therapy and Related Combination Therapies in the Treatment of Peyronie's Disease (an Update). Sexual Medicine Reviews, 2021, 9, 340-349.	2.9	12
11	Application of Botulinum Neurotoxin in Male Sexual Dysfunction: Where Are We Now?. Sexual Medicine Reviews, 2021, 9, 320-330.	2.9	7
12	Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature. Current Urology Reports, 2021, 22, 6.	2.2	8
13	Re: Effect of Natesto on Reproductive Hormones, Semen Parameters and Hypogonadal Symptoms: A Single Center, Open Label, Single Arm Trial. European Urology, 2021, 79, 890-891.	1.9	1
14	Tips and tricks in the management of inflatable penile prosthesis infection: A review. Arab Journal of Urology Arab Association of Urology, 2021, 19, 346-352.	1.5	0
15	Re: Testosterone Therapy in Men with Biochemical Recurrence and Metastatic Prostate Cancer: Initial Observations. Androgens: Clinical Research and Therapeutics, 2021, 2, 129-130.	0.5	Ο
16	Persistent Genital Arousal and Major Depressive Disorder in an Adolescent Male: Case Report and Discussion. Urology, 2021, , .	1.0	1
17	Options for Masculinizing Genital Gender Affirming Surgery: A Critical Review of the Literature and Perspectives for Future Directions. Sexual Medicine Reviews, 2021, 9, 605-618.	2.9	3
18	Updated Review of Testosterone Replacement Therapy in the Setting of Prostate Cancer. Androgens: Clinical Research and Therapeutics, 2021, 2, 36-45.	0.5	2

#	Article	IF	CITATIONS
19	The Management of Penile Fracture: a Review of the Literature with Special Consideration for Patients Undergoing Collagenase Clostridium Histolyticum Injection Therapy. Current Urology Reports, 2021, 22, 13.	2.2	9
20	Reviewing the evidence for shockwave- and cell-based regenerative therapies in the treatment of erectile dysfunction. Therapeutic Advances in Urology, 2021, 13, 175628722110020.	2.0	6
21	Neophallus Construction and Penile Prosthesis Implantation: Techniques and Complications. Current Sexual Health Reports, 2021, 13, 117-127.	0.8	Ο
22	Complex penile prosthesis reservoir extraction: a case series. International Journal of Impotence Research, 2020, 32, 122-125.	1.8	1
23	Retained Reservoirs of Inflatable Penile Prosthesis: A Systematic Review of the Literature and a Guide to Perioperative Management. Sexual Medicine Reviews, 2020, 8, 355-363.	2.9	5
24	Ivabradine, the hyperpolarization-activated cyclic nucleotide-gated channel blocker, elicits relaxation of the human corpus cavernosum: a potential option for erectile dysfunction treatment. Aging Male, 2020, 23, 1088-1097.	1.9	1
25	Analysis of the Symptomatology, Disease Course, and Treatment of Postorgasmic Illness Syndrome in a Large Sample. Journal of Sexual Medicine, 2020, 17, 2229-2235.	0.6	8
26	Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute Phase Peyronie's Disease: A Multi-institutional Analysis. Urology, 2020, 145, 147-151.	1.0	15
27	Testosterone positively regulates functional responses and nitric oxide expression in the isolated human corpus cavernosum. Andrology, 2020, 8, 1824-1833.	3.5	15
28	The Role of Hormones in Male Sexual Function. Current Sexual Health Reports, 2020, 12, 101-112.	0.8	2
29	Clomiphene Citrate for Male Hypogonadism and Infertility: An Updated Review. Androgens: Clinical Research and Therapeutics, 2020, 1, 62-69.	0.5	6
30	Current Perspectives on Complications of Surgical Treatments forÂMale Stress Urinary Incontinence. Sexual Medicine Reviews, 2020, 8, 443-449.	2.9	5
31	Harnessing Stem Cell Potential for the Treatment of Erectile Function in Men with Diabetes Mellitus: From Preclinical/Clinical Perspectives to Penile Tissue Engineering. Current Stem Cell Research and Therapy, 2020, 15, 308-320.	1.3	8
32	Prosthetic urology: past, present, and future. Asian Journal of Andrology, 2020, 22, 1.	1.6	8
33	Penile Prosthesis Complications: Planning, Prevention, and Decision Making. Sexual Medicine Reviews, 2019, 7, 349-359.	2.9	73
34	The Impact of Thyroid Disease on Sexual Dysfunction in Men and Women. Sexual Medicine Reviews, 2019, 7, 57-70.	2.9	61
35	The Use of Stromal Vascular Fraction in the Treatment of Male Sexual Dysfunction: A Review of Preclinical and Clinical Studies. Sexual Medicine Reviews, 2019, 7, 313-320.	2.9	11
36	Pioglitazone's beneficial effects on erectile function preservation after cavernosal nerve injury in the rat are negated by inhibition of the insulin-like growth factor-1 receptor: a preclinical study. International Journal of Impotence Research, 2019, 31, 1-8.	1.8	6

#	Article	IF	CITATIONS
37	Paediatric and adult-onset male hypogonadism. Nature Reviews Disease Primers, 2019, 5, 38.	30.5	153
38	An update on: long-term outcomes of penile prostheses for the treatment of erectile dysfunction. Expert Review of Medical Devices, 2019, 16, 281-286.	2.8	14
39	Sildenafil's impact on male infertility: what has changed in 20 years?. International Journal of Impotence Research, 2019, 31, 71-73.	1.8	9
40	Insulin-Like Growth Factor-1–Loaded Polymeric Poly(Lactic-Co-Glycolic) Acid Microspheres Improved Erectile Function in a Rat Model of Bilateral Cavernous Nerve Injury. Journal of Sexual Medicine, 2019, 16, 383-393.	0.6	11
41	Immediate Placement of Penile Prosthesis for the Management of Ischemic Priapism as First-line Treatment. European Urology Focus, 2019, 5, 531-532.	3.1	0
42	Vasectomy with vessel sealing device: comparison of different diameters. International Journal of Impotence Research, 2019, 31, 20-24.	1.8	2
43	Pharmacodynamics of the agents used for the treatment of erectile dysfunction. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 121-131.	3.3	6
44	Male Genital Dermatology: A Primer for the Sexual Medicine Physician. Sexual Medicine Reviews, 2019, 7, 71-83.	2.9	9
45	Penile Stretching as a Treatment for Peyronie's Disease: A Review. Sexual Medicine Reviews, 2019, 7, 508-515.	2.9	16
46	Unintended Consequences: A Review of Pharmacologically-Induced Priapism. Sexual Medicine Reviews, 2019, 7, 283-292.	2.9	18
47	Review of Management Options for Active-Phase Peyronie's Disease. Sexual Medicine Reviews, 2019, 7, 329-337.	2.9	29
48	Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis. Journal of Urology, 2019, 201, 777-782.	0.4	32
49	Male Orgasmic Dysfunction Post-Radical Pelvic Surgery. Sexual Medicine Reviews, 2018, 6, 429-437.	2.9	12
50	Post-Orgasmic Illness Syndrome: A Review. Sexual Medicine Reviews, 2018, 6, 11-15.	2.9	26
51	Comparison of Adjuvant Radiation Therapy Before or After Artificial Urinary Sphincter Placement: A Multi-Institutional, Retrospective Analysis. Urology, 2018, 113, 160-165.	1.0	4
52	Andrianne Mini-Jupette Graft at the Time of Inflatable Penile Prosthesis Placement for the Management of Post-Prostatectomy Climacturia and Minimal Urinary Incontinence. Journal of Sexual Medicine, 2018, 15, 789-796.	0.6	25
53	Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact. Sexual Medicine Reviews, 2018, 6, 143-156.	2.9	29
54	Bilateral Cavernous Nerve Crush Injury in the Rat Model: A Comparative Review of Pharmacologic Interventions. Sexual Medicine Reviews, 2018, 6, 234-241.	2.9	18

#	Article	IF	CITATIONS
55	Post-SSRI Sexual Dysfunction: A Literature Review. Sexual Medicine Reviews, 2018, 6, 29-34.	2.9	94
56	Advances in stem cell therapy for erectile dysfunction. Expert Opinion on Biological Therapy, 2018, 18, 1137-1150.	3.1	24
57	Multi-institutional Prospective Analysis of Intralesional Injection of Collagenase Clostridium Histolyticum, Tunical Plication, and Partial Plaque Excision and Grafting for the Management of Peyronie's Disease. Urology, 2018, 120, 138-142.	1.0	33
58	Grower or shower? Predictors of change in penile length from the flaccid to erect state. International Journal of Impotence Research, 2018, 30, 287-291.	1.8	6
59	The 2018 Revision to the Process of Care Model for Evaluation of Erectile Dysfunction. Journal of Sexual Medicine, 2018, 15, 1280-1292.	0.6	24
60	Role of Penile Prosthesis in Priapism: A Review. World Journal of Men?s Health, 2018, 36, 4.	3.3	25
61	The Effect of Adjunct Mechanical Traction on Penile Length in Men Undergoing Primary Treatment for Peyronie's Disease: A Systematic Review and Meta-analysis. Urology, 2018, 122, 110-115.	1.0	20
62	Contemporary Review of Grafting Techniques for the Surgical Treatment of Peyronie's Disease. Sexual Medicine Reviews, 2017, 5, 544-552.	2.9	63
63	Survey of patient and partner satisfaction following collagenase <i>Clostridium histolyticum</i> treatment for Peyronie's disease. Andrology, 2017, 5, 274-277.	3.5	15
64	Practice Patterns in the Diagnosis and Management of Hypogonadism: A Survey of Sexual Medicine Society of North America Members. Urology, 2017, 106, 87-95.	1.0	3
65	Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients With Peyronie Disease. Urology, 2017, 106, 237.e9-237.e14.	1.0	11
66	Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease. Urology, 2017, 107, 155-160.	1.0	30
67	The Conception and Evaluation of Sexual Health Literature. Sexual Medicine Reviews, 2017, 5, 135-145.	2.9	3
68	Successful Treatment of Residual Curvature in Peyronie Disease in Men Previously Treated With Intralesional Collagenase Clostridium Histolyticum. Urology, 2017, 110, 110-113.	1.0	18
69	Safety and Efficacy of Collagenase <i>Clostridium histolyticum</i> in the Treatment of Acute-Phase Peyronie's Disease. Journal of Sexual Medicine, 2017, 14, 1220-1225.	0.6	49
70	Re: Multicenter Investigation of the Micro-organisms Involved in Penile Prosthesis Infection: An Analysis of the Efficacy of the AUA and EAU Guidelines for Penile Prosthesis Prophylaxis. European Urology, 2017, 72, 854-855.	1.9	1
71	Erectile Dysfunction in Young Men—A Review of the Prevalence and Risk Factors. Sexual Medicine Reviews, 2017, 5, 508-520.	2.9	198
72	Characterisation of pomegranate juice effects on human corpus cavernosum. Andrologia, 2017, 49, e12712.	2.1	3

#	Article	IF	CITATIONS
73	Impact of Number of Cycles of Collagenase Clostridium Histolyticum on Outcomes in Patients With Peyronie's Disease. Urology, 2017, 100, 125-130.	1.0	43
74	Benign Prostatic Hyperplasia Treatment Options and Their Effects on Sexual Function. Sexual Medicine Reviews, 2017, 5, 87-102.	2.9	6
75	Review of Management Options for Patients With Atypical Peyronie's Disease. Sexual Medicine Reviews, 2017, 5, 211-221.	2.9	34
76	Device Survival after Primary Implantation of an Artificial Urinary Sphincter for Male Stress Urinary Incontinence. Journal of Urology, 2017, 197, 759-765.	0.4	32
77	Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option. World Journal of Men?s Health, 2017, 35, 134.	3.3	14
78	The dangers of sexual enhancement supplements and counterfeit drugs to "treat―erectile dysfunction. Translational Andrology and Urology, 2017, 6, 12-19.	1.4	36
79	Collagenase Clostridium histolyticum in the treatment of Peyronie’s disease: patient selection and perspectives. Patient Preference and Adherence, 2017, Volume 11, 431-448.	1.8	9
80	Racial variations in response to intralesional collagenase clostridium histolyticum in men with Peyronie's disease. Translational Andrology and Urology, 2017, 6, 888-893.	1.4	4
81	Effect of collagenase Clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie's disease. Translational Andrology and Urology, 2017, 6, 894-898.	1.4	7
82	Current updates on laboratory techniques for the diagnosis of male reproductive failure. Asian Journal of Andrology, 2016, 18, 392.	1.6	63
83	The pathophysiology of acquired premature ejaculation. Translational Andrology and Urology, 2016, 5, 434-449.	1.4	67
84	Effect of adipose tissue-derived stem cell injection in a rat model of urethral fibrosis. Canadian Urological Association Journal, 2016, 10, 175.	0.6	22
85	Intralesional collagenase clostridium histolyticum study provides real-world analysis. Translational Andrology and Urology, 2016, 5, 951-952.	1.4	0
86	Surgery is not indicated for the treatment of premature ejaculation. Translational Andrology and Urology, 2016, 5, 607-612.	1.4	8
87	Modifying Risk Factors in the Management of Erectile Dysfunction: A Review. World Journal of Men?s Health, 2016, 34, 89.	3.3	64
88	Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. Research and Reports in Urology, 2016, Volume 8, 123-131.	1.0	13
89	Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction?. BJU International, 2016, 118, 464-474.	2.5	21
90	Semen proteome alterations in the smoking male: a nonâ€generalizable study. BJU International, 2016, 118, 673-674.	2.5	0

#	Article	IF	CITATIONS
91	Contemporary Review of Artificial Urinary Sphincters for Male Stress Urinary Incontinence. Sexual Medicine Reviews, 2016, 4, 157-166.	2.9	30
92	The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer. Sexual Medicine Reviews, 2016, 4, 74-84.	2.9	40
93	Outcomes of Surgical Management of Men With Peyronie's Disease With Hourglass Deformity. Urology, 2016, 91, 119-123.	1.0	11
94	Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy with Collagenase Clostridium Histolyticum for Peyronie's Disease. Journal of Sexual Medicine, 2016, 13, 684-689.	0.6	44
95	Collagenase <i>Clostridium histolyticum</i> in the management of Peyronie's disease: a review of the evidence. Therapeutic Advances in Urology, 2016, 8, 192-202.	2.0	6
96	Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact. Expert Opinion on Pharmacotherapy, 2016, 17, 2281-2289.	1.8	3
97	Injection Therapy for Peyronie's Disease. , 2016, , 301-313.		0
98	Avanafil for the treatment of erectile dysfunction. Expert Review of Clinical Pharmacology, 2016, 9, 1163-1170.	3.1	14
99	Adult-Onset Hypogonadism. Mayo Clinic Proceedings, 2016, 91, 908-926.	3.0	74
100	Erectile dysfunction. Nature Reviews Disease Primers, 2016, 2, 16003.	30.5	475
101	Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease: A â€~Real World' Clinical Perspective. Drugs, 2016, 76, 1523-1528.	10.9	7
102	Can Adipose-derived Stem Cells Be Used in the Treatment of Urethral Stricture Disease?. European Urology, 2016, 70, 1042-1043.	1.9	2
103	Diabetes and Sexual Function. Current Sexual Health Reports, 2016, 8, 9-18.	0.8	1
104	Adipose Tissue-Derived Stem Cells for the Treatment of Erectile Dysfunction. Current Urology Reports, 2016, 17, 14.	2.2	22
105	Current Perspectives on Stem Cell Therapy for Erectile Dysfunction. Sexual Medicine Reviews, 2016, 4, 247-256.	2.9	28
106	Pioglitazone Enhances Survival and Regeneration of Pelvic Ganglion Neurons After Cavernosal Nerve Injury. Urology, 2016, 89, 76-82.	1.0	9
107	Current state of affairs of Peyronie's disease. Translational Andrology and Urology, 2016, 5, 278-279.	1.4	0
108	Penile Priapism, Clitoral Priapism, and Persistent Genital Arousal Disorder: A Contemporary Review. Sexual Medicine Reviews, 2015, 3, 145-159.	2.9	9

#	Article	IF	CITATIONS
109	Erectile dysfunction in urethral stricture and pelvic fracture urethral injury patients: diagnosis, treatment, and outcomes. Andrology, 2015, 3, 443-449.	3.5	33
110	Evaluation of collagenase Clostridium histolyticum for the treatment of Peyronie's disease. Expert Opinion on Orphan Drugs, 2015, 3, 1331-1338.	0.8	0
111	Comparative Analysis of Tunical Plication vs. Intralesional Injection Therapy for Ventral Peyronie's Disease. Journal of Sexual Medicine, 2015, 12, 2492-2498.	0.6	12
112	Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male. Sexual Medicine Reviews, 2015, 3, 101-112.	2.9	56
113	Therapeutic advances in the treatment of Peyronie's disease. Andrology, 2015, 3, 650-660.	3.5	40
114	Failure to attain stretched penile length after intracavernosal injection of a vasodilator agent is predictive of veno-occlusive dysfunction on penile duplex Doppler ultrasonography. Andrology, 2015, 3, 919-923.	3.5	11
115	Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study. Journal of Urology, 2015, 194, 485-492.	0.4	28
116	Emerging drugs for the treatment of erectile dysfunction. Expert Opinion on Emerging Drugs, 2015, 20, 263-275.	2.4	29
117	Intralesional Injection of Interferon-α2b Improves Penile Curvature in Men with Peyronie's Disease Independent of Plaque Location. Journal of Urology, 2015, 194, 1704-1707.	0.4	49
118	Collagenase Clostridium histolyticum (Xiaflex) for the Treatment of Urethral Stricture Disease in a Rat Model of Urethral Fibrosis. Urology, 2015, 86, 647.e1-647.e6.	1.0	29
119	Strategies for Penile Prosthesis Placement in Peyronie's Disease and Corporal Fibrosis. Current Urology Reports, 2015, 16, 21.	2.2	26
120	The Effect of Duration of Penile Traction Therapy in Patients Undergoing Intralesional Injection Therapy for Peyronie's Disease. Journal of Urology, 2015, 194, 754-758.	0.4	57
121	Transforming Growth Factor-β1 Induced Urethral Fibrosis in a Rat Model. Journal of Urology, 2015, 194, 820-827.	0.4	35
122	Pregabalin Does Not Affect Sperm Production in Healthy Volunteers: A Randomized, Doubleâ€blind, Placeboâ€controlled, Noninferiority Study. Pain Practice, 2015, 15, 150-158.	1.9	11
123	Self-report and Clinical Response to Peyronie's Disease Treatment: Peyronie's Disease Questionnaire Results From 2 Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies. Urology, 2015, 86, 291-299.	1.0	28
124	Overview of potential molecular targets for hydrogen sulfide: A new strategy for treating erectile dysfunction. Nitric Oxide - Biology and Chemistry, 2015, 50, 65-78.	2.7	16
125	Reply. Urology, 2015, 86, 299.	1.0	1
126	The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. Journal of Sexual Medicine, 2015, 12, 1660-1686.	0.6	119

#	Article	IF	CITATIONS
127	2015 Update of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research to Clinical Management. Current Pharmaceutical Design, 2015, 21, 1440-1454.	1.9	7
128	Commentary on "validation of robot-assisted vasectomy reversal". Asian Journal of Andrology, 2015, 17, 332.	1.6	1
129	Cyclingâ€Related Sexual Dysfunction in Men and Women: A Review. Sexual Medicine Reviews, 2014, 2, 93-101.	2.9	16
130	An Evidence-Based Unified Definition of Lifelong and Acquired Premature Ejaculation: Report of the Second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. Sexual Medicine, 2014, 2, 41-59.	1.6	174
131	Clinical Use of Aromatase Inhibitors in Adult Males. Sexual Medicine Reviews, 2014, 2, 79-90.	2.9	23
132	Testosterone and the Prostate. Sexual Medicine Reviews, 2014, 2, 112-120.	2.9	1
133	Phosphodiesterase type 5 inhibitors for stuttering priapism: recent advances. Expert Opinion on Orphan Drugs, 2014, 2, 937-946.	0.8	Ο
134	Pioglitazone prevents cavernosal nerve injury after radical prostatectomy. Medical Hypotheses, 2014, 82, 504.	1.5	3
135	Intracorporeal Robot-Assisted Microsurgical Vasovasostomy for the Treatment of Bilateral Vasal Obstruction Occurring Following Bilateral Inguinal Hernia Repairs with Mesh Placement. Journal of Urology, 2014, 191, 1120-1125.	0.4	26
136	Efficacy of Pioglitazone on Erectile Function Recovery in a Rat Model of Cavernous Nerve Injury. Urology, 2014, 84, 1122-1127.	1.0	19
137	Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease. Andrology, 2014, 2, 244-251.	3.5	75
138	Update on Medical Management of Peyronie's Disease. Current Urology Reports, 2014, 15, 415.	2.2	19
139	Review of Erectile Dysfunction in Diabetic Animal Models. Current Diabetes Reviews, 2014, 10, 61-73.	1.3	24
140	A phase <scp>II</scp> , singleâ€blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction. BJU International, 2013, 111, 137-147.	2.5	27
141	History, Contemporary Outcomes, and Future of Penile Prostheses: A Review of the Literature. Sexual Medicine Reviews, 2013, 1, 150-163.	2.9	30
142	Sirt3 modulation may be beneficial in the treatment of ejaculation dysfunction. Medical Hypotheses, 2013, 81, 448-449.	1.5	0
143	Long-term outcomes of penile prostheses for the treatment of erectile dysfunction. Expert Review of Medical Devices, 2013, 10, 353-366.	2.8	60
144	State of the art: medical treatment of Peyronie's disease. Expert Opinion on Orphan Drugs, 2013, 1, 867-876.	0.8	0

#	Article	IF	CITATIONS
145	Understanding the course of Peyronie's disease. International Journal of Clinical Practice, 2013, 67, 781-788.	1.7	62
146	Standardization of Vascular Assessment of Erectile Dysfunction. Journal of Sexual Medicine, 2013, 10, 120-129.	0.6	136
147	Bother and Distress Associated with Peyronie's Disease: Validation of the Peyronie's Disease Questionnaire. Journal of Urology, 2013, 190, 627-634.	0.4	176
148	A critical analysis of the surgical outcomes for the treatment of Peyronie's disease. Arab Journal of Urology Arab Association of Urology, 2013, 11, 284-293.	1.5	11
149	Imatinib Mesylate (Gleevec) Induces HumanÂCorpus Cavernosum Relaxation byÂlnhibiting Receptor Tyrosine Kinases (RTKs):Âldentification of New RTK Targets. Urology, 2013, 82, 745.e11-745.e16.	1.0	13
150	Outcomes of Intralesional Interferon-α2B for the Treatment of Peyronie Disease. Journal of Urology, 2013, 190, 2194-2199.	0.4	48
151	Re: Long-Term Infection Outcomes of 3-Piece Antibiotic Impregnated Penile Prostheses Used in Replacement Implant Surgery. Journal of Urology, 2013, 189, 1994-1996.	0.4	0
152	Adolescent varicocoele management controversies. Andrology, 2013, 1, 109-115.	3.5	16
153	Clinical Efficacy, Safety and Tolerability of Collagenase Clostridium Histolyticum for the Treatment of Peyronie Disease in 2 Large Double-Blind, Randomized, Placebo Controlled Phase 3 Studies. Journal of Urology, 2013, 190, 199-207.	0.4	400
154	Side Effects of 5â€Alpha Reductase Inhibitors: A Comprehensive Review. Sexual Medicine Reviews, 2013, 1, 24-41.	2.9	38
155	Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opinion on Drug Safety, 2013, 12, 81-90.	2.4	71
156	Current and emerging treatment options for Peyronie's disease. Research and Reports in Urology, 2013, 5, 17.	1.0	11
157	The pre-treatment prevalence and types of sexual dysfunction among patients diagnosed with prostate cancer. Andrology, 2013, 1, 859-863.	3.5	14
158	Testosterone Deficiency, Supplementation, and Prostate Cancer: Maintaining a Balanced Perspective. Journal of Sexual Medicine, 2013, 10, 2879-2881.	0.6	3
159	Managing the Difficult Penile Prosthesis Patient. Journal of Sexual Medicine, 2013, 10, 893-907.	0.6	69
160	Baseline Characteristics from an Ongoing Phase 3 Study of Collagenase Clostridium Histolyticum in Patients with Peyronie's Disease. Journal of Sexual Medicine, 2013, 10, 2822-2831.	0.6	43
161	Collagenase clostridium histolyticum: a novel nonsurgical option for the treatment of Peyronie's disease. International Journal of Clinical Rheumatology, 2013, 8, 531-540.	0.3	0
162	Activation of P2Y1 and P2Y2 nucleotide receptors by adenosine 5′-triphosphate analogues augmented nerve-mediated relaxation of human corpus cavernosum. Canadian Urological Association Journal, 2013, 3, 314.	0.6	6

#	Article	IF	CITATIONS
163	Dapoxetine and the treatment of premature ejaculation. Translational Andrology and Urology, 2013, 2, 301-11.	1.4	8
164	The Clinical Diagnosis of Androgen Deficiency. , 2013, , 33-39.		0
165	Premature ejaculation: do we have effective therapy?. Translational Andrology and Urology, 2013, 2, 45-53.	1.4	7
166	Adipose tissue-derived stem cell-seeded small intestinal submucosa for tunica albuginea grafting and reconstruction. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2090-2095.	7.1	57
167	Long-Term Revision Rate Due to Infection in Hydrophilic-Coated Inflatable Penile Prostheses: 11-Year Follow-up. Journal of Sexual Medicine, 2012, 9, 2182-2186.	0.6	58
168	Re: Long-Term Infection Outcomes After Original Antibiotic Impregnated Inflatable Penile Prosthesis Implants: Up to 7.7 Years of Followup. Journal of Urology, 2012, 187, 1936-1937.	0.4	0
169	1480 ONSET OF ACTION AND TIME TO EFFICACY OF AVANAFIL, A NOVEL, RAPID-ONSET PDE5 INHIBITOR IN MEN WITH MILD TO SEVERE ERECTILE DYSFUNCTION DATA FROM PHASE 2 AND PHASE 3 CLINICAL TRIALS. Journal of Urology, 2012, 187, .	0.4	2
170	Drugs of the future for Peyronie's disease. Medical Hypotheses, 2012, 78, 305-311.	1.5	7
171	Re: Prevalence of ejaculatory disorders in urban men-results of a random-sample survey. Andrologia, 2012, 44, 365-365.	2.1	0
172	Sexual Dysfunction Following Radical Prostatectomy. Journal of Andrology, 2012, 33, 1143-1154.	2.0	25
173	Infection Retardant Coated Inflatable Penile Prostheses Decrease the Incidence of Infection: A Systematic Review and Meta-Analysis. Journal of Urology, 2012, 188, 1855-1860.	0.4	100
174	Re: Hartmut Porst, Edward D. Kim, Adolfo R. Casabé, et al., for the LVHJ study team. Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial. Eur Urol 2011;60:1105–13. European Urology, 2012, 61, e45-e46.	1.9	6
175	Multipotent Stromal Cell Therapy for Cavernous Nerve Injury-Induced Erectile Dysfunction. Journal of Sexual Medicine, 2012, 9, 385-403.	0.6	60
176	Incomplete Recovery of Erectile Function in Rat after Discontinuation of Dual 5â€Alpha Reductase Inhibitor Therapy. Journal of Sexual Medicine, 2012, 9, 1773-1781.	0.6	29
177	Inhibition of sympathetic neuroeffector transmission in human corpus cavernosum. BJU International, 2012, 110, 856-862.	2.5	9
178	Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review. International Urology and Nephrology, 2012, 44, 61-70.	1.4	24
179	Medical Management of Peyronie's Disease. , 2012, , 429-437.		0
180	Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options. Expert Opinion on Pharmacotherapy, 2011, 12, 931-944.	1.8	66

#	Article	IF	CITATIONS
181	Imatinib Mesylate (Gleevec) as Protein-tyrosine Kinase Inhibitor Elicits Smooth Muscle Relaxation in Isolated Human Prostatic Tissue. Urology, 2011, 78, 968.e1-968.e6.	1.0	12
182	Using Wound Drains for the Uncomplicated Penile Prosthesis. Journal of Urology, 2011, 186, 1187-1189.	0.4	8
183	The link between penile hypersensitivity and premature ejaculation. BJU International, 2011, 107, 452-457.	2.5	33
184	Update on treatments for premature ejaculation. International Journal of Clinical Practice, 2011, 65, 16-26.	1.7	34
185	RhoA/Rhoâ€Kinase as a Therapeutic Target for the Male Urogenital Tract. Journal of Sexual Medicine, 2011, 8, 675-687.	0.6	15
186	The Effects of Chronic 5-Alpha-Reductase Inhibitor (Dutasteride) Treatment on Rat Erectile Function. Journal of Sexual Medicine, 2011, 8, 3066-3074.	0.6	58
187	Re: Treatment of Erectile Dysfunction in the Obese Type 2 Diabetic ZDF Rat With Adipose Tissue-Derived Stem Cells. European Urology, 2011, 59, 168-169.	1.9	4
188	Treatment of Peyronie's Disease: 2012 Update. Current Urology Reports, 2011, 12, 444-452.	2.2	45
189	Chronic inhibition of nitricâ€oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil. BJU International, 2010, 106, 78-83.	2.5	28
190	Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction. Current Pharmaceutical Design, 2010, 16, 1619-1633.	1.9	25
191	New Concepts in the Diagnosis and Treatment of Premature Ejaculation. Current Urology Reports, 2010, 11, 414-420.	2.2	5
192	Implants, Mechanical Devices, and Vascular Surgery for Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 501-523.	0.6	127
193	International Society for Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature Ejaculation. Journal of Sexual Medicine, 2010, 7, 2947-2969.	0.6	289
194	Amelioration of gentamicin nephrotoxicity by green tea extract in uninephrectomized rats as a model of progressive renal failure. Renal Failure, 2010, 32, 1210-1215.	2.1	16
195	Hypogonadism, ADAM, and hormone replacement. Therapeutic Advances in Urology, 2010, 2, 99-104.	2.0	17
196	Transplantation of Nonhematopoietic Adult Bone Marrow Stem/Progenitor Cells Isolated by p75 Nerve Growth Factor Receptor Into the Penis Rescues Erectile Function in a Rat Model of Cavernous Nerve Injury. Journal of Urology, 2010, 184, 1560-1566.	0.4	87
197	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opinion on Investigational Drugs, 2010, 19, 1427-1437.	4.1	72
198	Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opinion on Pharmacotherapy, 2010, 11, 1109-1122.	1.8	72

#	Article	IF	CITATIONS
199	Purinergic contraction of the rat vas deferens in L-NAME-induced hypertension: effect of sildenafil. Asian Journal of Andrology, 2010, 12, 415-421.	1.6	5
200	Does erectile dysfunction drug use contribute to risky sexual behavior?. Asian Journal of Andrology, 2010, 12, 626-627.	1.6	3
201	Available and future therapies for premature ejaculation. Drugs of Today, 2010, 46, 507.	1.1	1
202	Emerging treatments for premature ejaculation: focus on dapoxetine. Neuropsychiatric Disease and Treatment, 2009, 5, 37.	2.2	41
203	Sex and the Infertile Male. Seminars in Reproductive Medicine, 2009, 27, 186-190.	1.1	13
204	Ejaculatory Dysfunction and Its Association With Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia and BPH Treatment. Urology, 2009, 74, 15-21.	1.0	39
205	Reply by the Author. Urology, 2009, 74, 1377-1378.	1.0	1
206	Medical Management of Peyronie's Disease. Journal of Andrology, 2009, 30, 397-405.	2.0	59
207	Characterization of Erectile Function in Monocrotaline-Treated Pulmonary Hypertensive Rats. Journal of Andrology, 2009, 30, 495-504.	2.0	6
208	Effects of Alfuzosin and Tamsulosin on Sperm Parameters in Healthy Men: Results of a Shortâ€Term, Randomized, Doubleâ€Blind, Placeboâ€Controlled, Crossover Study. Journal of Andrology, 2009, 30, 469-474.	2.0	35
209	Premature ejaculation: current and future treatments. Asian Journal of Andrology, 2008, 10, 102-109.	1.6	32
210	The pharmacological treatment of premature ejaculation. BJU International, 2008, 102, 668-675.	2.5	80
211	An evidenceâ€based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU International, 2008, 102, 338-350.	2.5	125
212	Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. BJU International, 2008, 102, 1651-1657.	2.5	23
213	An Evaluation of Semen Characteristics in Men 45 Years of Age or Older after Daily Dosing with Tadalafil 20mg: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, 9-Month Study. European Urology, 2008, 53, 1058-1065.	1.9	57
214	Reply to Giorgio Pomara, Domenico Canale, Paolo Turchi and Francesco Francesca's Letter to the Editor re: Wayne J.G. Hellstrom, Marc Gittelman, Jonathan Jarow, et al. An Evaluation of Semen Characteristics in Men 45 Years of Age or Older after Daily Dosing with Tadalafil 20 mg: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, 9-Month Study. Eur Urol 2008;53:1058–65.	1.9	0
215	European Urology, 2008, 53, 1090-1091. An Evidence-Based Definition of Lifelong Premature Ejaculation: Report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the Definition of Premature Ejaculation. Journal of Sexual Medicine, 2008, 5, 1590-1606.	0.6	353
216	5-Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection. Journal of Sexual Medicine, 2008, 5, 2917-2924.	0.6	68

#	Article	IF	CITATIONS
217	Guide to Drug Therapy for Lower Urinary Tract Symptoms in Patients with Benign Prostatic Obstruction. Drugs, 2008, 68, 209-229.	10.9	17
218	A review of current progress in gene and stem cell therapy for erectile dysfunction. Expert Opinion on Biological Therapy, 2008, 8, 1521-1538.	3.1	14
219	Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opinion on Investigational Drugs, 2008, 17, 855-864.	4.1	19
220	Introduction: centrally acting agents in male sexual dysfunction. International Journal of Impotence Research, 2008, 20, S1-S2.	1.8	0
221	Clinical applications of centrally acting agents in male sexual dysfunction. International Journal of Impotence Research, 2008, 20, S17-S23.	1.8	18
222	Nursing practice: a primary care approach to intralesional injection therapy for Peyronie's disease. International Journal of Urological Nursing, 2008, 2, 78-84.	0.2	0
223	Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1278-H1290.	3.2	133
224	Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1340-H1351.	3.2	85
225	The Effect of Vascular Risk Factors on Penile Vascular Status in Men With Erectile Dysfunction. Journal of Urology, 2007, 178, 2516-2520.	0.4	43
226	Optimizing Nitric Oxide Production by Time Dependent L-Arginine Administration in Isolated Human Corpus Cavernosum. Journal of Urology, 2007, 178, 1543-1548.	0.4	24
227	Pharmacological Management of Peyronie???s Disease. Drugs, 2007, 67, 527-545.	10.9	34
228	The Role of Endothelium in Erectile Function and Dysfunction. , 2007, , 1541-1549.		2
229	Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: influence of in vivo gene therapy of PKG1?. BJU International, 2007, 99, 1488-1494.	2.5	35
230	Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. International Journal of Clinical Practice, 2007, 61, 1547-1554.	1.7	24
231	Peripheral Mechanisms of Erectile Dysfunction in a Rat Model of Chronic Cocaine Use. European Urology, 2007, 52, 555-564.	1.9	14
232	Controversies in the laboratory evaluation of hypogonadism: Androgen deficiency algorithm. Current Sexual Health Reports, 2007, 4, 51-55.	0.8	0
233	Intralesional Treatment of Peyronie's Disease. , 2007, , 81-92.		1
234	Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. Therapeutics and Clinical Risk Management, 2007, 3, 277-289.	2.0	42

#	Article	IF	CITATIONS
235	Single-Blind, Multicenter, Placebo Controlled, Parallel Study to Assess the Safety and Efficacy of Intralesional Interferon α-2b for Minimally Invasive Treatment for Peyronie's Disease. Journal of Urology, 2006, 176, 394-398.	0.4	195
236	Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet, The, 2006, 368, 929-937.	13.7	301
237	Semen and Sperm Reference Ranges for Men 45 Years of Age and Older. Journal of Andrology, 2006, 27, 421-428.	2.0	103
238	Effects of Acute Treatment With Tamsulosin Versus Alfuzosin on Ejaculatory Function in Normal Volunteers. Journal of Urology, 2006, 176, 1529-1533.	0.4	192
239	Update on erectile dysfunction in prostate cancer patients. Current Opinion in Urology, 2006, 16, 186-195.	1.8	53
240	Management of sildenafil treatment failures. Current Opinion in Urology, 2006, 16, 449-459.	1.8	44
241	Treatment of premature ejaculation: New drugs and treatment strategies. Current Sexual Health Reports, 2006, 3, 177-182.	0.8	0
242	Treatment of premature ejaculation: new drugs and treatment strategies. Current Urology Reports, 2006, 7, 473-478.	2.2	5
243	Current and Future Pharmacotherapies of Premature Ejaculation. Journal of Sexual Medicine, 2006, 3, 332-341.	0.6	30
244	Gene Therapy for Erectile Dysfunction: Fact or Fiction?. European Urology, 2006, 50, 1208-1222.	1.9	39
245	Persistent penile abnormalities in men with Peyronie's disease. Nature Reviews Urology, 2006, 3, 634-635.	1.4	0
246	Radical Prostatectomy and Other Pelvic Surgeries. , 2006, , 135-154.		3
247	Erectile dysfunction in the aging man: current options for treatment. Aging Health, 2006, 2, 71-86.	0.3	1
248	Current concepts in ejaculatory dysfunction. Reviews in Urology, 2006, 8 Suppl 4, S18-25.	0.9	14
249	The Impact of Intralesional Interferon αâ€2b Injection Therapy on Penile Hemodynamics in Men with Peyronie's Disease. Journal of Sexual Medicine, 2005, 2, 709-715.	0.6	52
250	ORIGINAL RESEARCH—BASIC SCIENCE: Superoxide Anion Production in the Rat Penis Impairs Erectile Function in Diabetes: Influence of In Vivo Extracellular Superoxide Dismutase Gene Therapy. Journal of Sexual Medicine, 2005, 2, 187-198.	0.6	118
251	Controversies regarding testosterone supplementation in the prostate cancer patient. Current Sexual Health Reports, 2005, 2, 41-44.	0.8	0
252	Endothelial Nitric Oxide Synthase Gene Therapy for Erectile Dysfunction. Current Pharmaceutical Design, 2005, 11, 4059-4067.	1.9	27

#	Article	IF	CITATIONS
253	POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE INHIBITION PRESERVES ERECTILE FUNCTION IN RATS AFTER CAVERNOUS NERVE INJURY. Journal of Urology, 2005, 174, 2054-2059.	0.4	29
254	THE RELATIONSHIP BETWEEN THE TYPE OF PENILE ABNORMALITY AND PENILE VASCULAR STATUS IN PATIENTS WITH PEYRONIE'S DISEASE. Journal of Urology, 2005, 174, 632-635.	0.4	33
255	Vardenafil in Patients With Erectile Dysfunction: Achieving Treatment Optimization. Journal of Andrology, 2005, 26, 604-609.	2.0	15
256	Strategic Therapies for Ejaculatory Disorders and Erectile Dysfunction in the Infertile Man. , 2005, , 169-181.		0
257	Testosterone Replacement Therapy. Scientific World Journal, The, 2004, 4, 142-149.	2.1	3
258	Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction. Expert Opinion on Pharmacotherapy, 2004, 5, 923-932.	1.8	14
259	RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9121-9126.	7.1	297
260	The protective effect of aminoguanidine on erectile function in diabetic rats is not related to the timing of treatment. BJU International, 2004, 94, 429-432.	2.5	23
261	Feline penile erection induced by topical glans penis application of combination alprostadil and SEPA (Topiglan). International Journal of Impotence Research, 2004, 16, 73-77.	1.8	9
262	The Hydrophilicâ€Coated Inflatable Penile Prosthesis: 1â€Year Experience. Journal of Sexual Medicine, 2004, 1, 221-224.	0.6	116
263	The Penile Implant for Erectile Dysfunction. Journal of Sexual Medicine, 2004, 1, 98-109.	0.6	62
264	STRATIFICATION OF PENILE VASCULAR PATHOLOGIES IN PATIENTS WITH PEYRONIE'S DISEASE AND IN MEN WITH ERECTILE DYSFUNCTION ACCORDING TO AGE: A COMPARATIVE STUDY. Journal of Urology, 2004, 172, 259-262.	0.4	44
265	Relationship Between the Severity of Penile Curvature and the Presence of Comorbidities in Men With Peyronie's Disease. Journal of Urology, 2004, 171, 775-779.	0.4	52
266	Current Concepts in the Management of Erectile Dysfunction in Men with Prostate Cancer. Clinical Prostate Cancer, 2004, 3, 87-92.	2.1	50
267	RE: OPTIMIZING TREATMENT FOR DIABETES MELLITUS INDUCED ERECTILE DYSFUNCTION. Journal of Urology, 2004, 171, 1638-1639.	0.4	0
268	Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology, 2004, 64, 1187-1195.	1.0	31
269	Critical analysis of surgery for Peyronie's disease. Current Opinion in Urology, 2004, 14, 381-388.	1.8	83
270	Intralesional Interferon-α-2B Injections for the Treatment of Peyronie's Disease. Southern Medical Journal, 2004, 97, 42-46.	0.7	39

#	Article	IF	CITATIONS
271	Benign prostatic hyperplasia, sexual function, and overall evaluation of the male patient. Journal of the American Osteopathic Association, The, 2004, 104, S5-10.	1.7	3
272	Intranasal apomorphine. Nastech Pharmaceutical. IDrugs: the Investigational Drugs Journal, 2004, 7, 483-8.	0.7	3
273	Vardenafil: A new approach to the treatment of erectile dysfunction. Current Urology Reports, 2003, 4, 479-487.	2.2	29
274	Testicularâ€sparing surgery: a reasonable option in selected patients with testicular lesions. BJU International, 2003, 91, 337-340.	2.5	30
275	Antimicrobial activity of antibiotic-soaked, Resistâ,,¢-coated Bioflex®. International Journal of Impotence Research, 2003, 15, 18-21.	1.8	27
276	Surgical approaches for advanced Peyronie's disease patients. International Journal of Impotence Research, 2003, 15, S121-S124.	1.8	20
277	Three-piece inflatable penile prosthesis components (surgical pearls on reservoirs, pumps, and rear-tip) Tj ETQq1	l 0.78431 1.8	4 rgBT /Over
278	Gene Transfer of Endothelial Nitric Oxide Synthase Partially Restores Nitric Oxide Synthesis and Erectile Function in Streptozotocin Diabetic Rats. Journal of Urology, 2003, 169, 1911-1917.	0.4	133
279	Tadalafil has No Detrimental Effect on Human Spermatogenesis or Reproductive Hormones. Journal of Urology, 2003, 170, 887-891.	0.4	128
280	Cavernous Neurotomy Causes Hypoxia and Fibrosis in Rat Corpus Cavernosum. Journal of Andrology, 2003, 24, 239-245.	2.0	263
281	Endothelial Dysfunction in Erectile Dysfunction: Role of the Endothelium in Erectile Physiology and Disease. Journal of Andrology, 2003, 24, S17-37.	2.0	222
282	Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology, 2003, 61, 8-14.	1.0	136
283	Patient and partner satisfaction and long-term results after surgical treatment for Peyronie's disease. Urology, 2003, 62, 105-109.	1.0	89
284	Gene transfer of extracellular SOD to the penis reduces O 2 â^' · and improves erectile function in aged rats. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H1408-H1421.	3.2	101
285	Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochemical and Biophysical Research Communications, 2002, 298, 427-432.	2.1	57
286	Localization of Peripheral Dopamine D1 and D2 Receptors in Rat and Human Seminal Vesicles. Journal of Andrology, 2002, 23, 114-120.	2.0	15
287	The molecular basis of erectile physiology: from bench to bedside. Journal of Andrology, 2002, 23, S3-4.	2.0	2
288	Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. Journal of Andrology, 2002, 23, 763-71.	2.0	206

#	Article	IF	CITATIONS
289	Increased Expression of Arginase II in Human Diabetic Corpus Cavernosum: In Diabetic-Associated Erectile Dysfunction. Biochemical and Biophysical Research Communications, 2001, 283, 923-927.	2.1	195
290	INTRACAVERNOSAL INJECTION AND INTRAURETHRAL THERAPY FOR ERECTILE DYSFUNCTION. Urologic Clinics of North America, 2001, 28, 343-354.	1.8	44
291	Androgen deficiency in the aging male: Pathophysiology, diagnosis, and treatment alternatives. Current Urology Reports, 2001, 2, 473-479.	2.2	8
292	Role of genitourinary inflammation in infertility: synergistic effect of lipopolysaccharide and interferon-gamma on human spermatozoa. Journal of Developmental and Physical Disabilities, 2001, 24, 136-141.	3.6	22
293	Functional measurements of penile erection in feline, canine and primate animal models. International Journal of Impotence Research, 2001, 13, 149-150.	1.8	4
294	Gene Transfer of Prepro-Calcitonin Gene-Related Peptide Restores Erectile Function in the Aged Rat1. Biology of Reproduction, 2001, 65, 1371-1377.	2.7	79
295	Peyronie's disease: Advances in basic science and pathophysiology. Current Urology Reports, 2000, 1, 297-301.	2.2	21
296	Pharmacotherapy for erectile dysfunction. Trends in Pharmacological Sciences, 2000, 21, 484-489.	8.7	97
297	APPLICATION OF PERICARDIAL GRAFT IN THE SURGICAL MANAGEMENT OF PEYRONIE'S DISEASE. Journal of Urology, 2000, 163, 1445-1447.	0.4	109
298	A RAT MODEL OF PEYRONIE'S DISEASE ASSOCIATED WITH A DECREASE IN ERECTILE ACTIVITY AND AN INCREASE IN INDUCIBLE NITRIC OXIDE SYNTHASE PROTEIN EXPRESSION. Journal of Urology, 2000, 163, 1992-1998.	0.4	103
299	Feline penile erection induced by transurethral administration of sodium nitroprusside. Urological Research, 1999, 27, 432-436.	1.5	10
300	POTENTIATION OF ERECTILE RESPONSE AND cAMP ACCUMULATION BY COMBINATION OF PROSTAGLANDIN E 1 AND ROLIPRAM, A SELECTIVE INHIBITOR OF THE TYPE 4 PHOSPHODIESTERASE (PDE 4). Journal of Urology, 1999, 162, 1848-1855.	0.4	34
301	EFFECTS OF ALPROSTADIL AND PRAZOSIN ON MOTILITY, VIABILITY AND MEMBRANE INTEGRITY OF HUMAN SPERM. Journal of Urology, 1998, 159, 1559-1562.	0.4	11
302	EFFICACY AND SAFETY OF TRANSURETHRAL ALPROSTADIL IN PATIENTS WITH ERECTILE DYSFUNCTION FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 1998, 160, 1325-1328.	0.4	100
303	Treatment of Men with Erectile Dysfunction with Transurethral Alprostadil. New England Journal of Medicine, 1997, 336, 1-7.	27.0	622
304	Penile calciphylaxis. Urology, 1997, 50, 622-624.	1.0	30
305	A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology, 1996, 48, 851-856.	1.0	80
306	Posttraumatic High Flow Internal Pudendal Artery-Urethral Fistula. Journal of Urology, 1995, 153, 734-736.	0.4	5

#	Article	IF	CITATIONS
307	Reproductive capacity of the nucleus of the male gamete after completion of meiosis. Journal of Assisted Reproduction and Genetics, 1994, 11, 335-341.	2.5	107
308	Newer Modalities in the Diagnosis and Treatment of Ejaculatory Duct Obstruction. Journal of Urology, 1993, 150, 1150-1154.	0.4	84
309	Bilateral Renal Parenchymal Malacoplakia: A Case Report. Journal of Urology, 1992, 147, 115-117.	0.4	18
310	Potassium channel agonists cause penile erection in cats. International Journal of Impotence Research, 1992, 4, 35-43.	1.8	10
311	Antisperm Antibodies Bind With Different Patterns to Sperm of Different Men. Journal of Urology, 1987, 138, 895-898.	0.4	15
312	Diagnosis and Treatment of Male Ejaculatory Dysfunction. , 0, , 187-192.		0
313	Are neutrophil–lymphocyte and platelet–lymphocyte ratios useful for determining active phase of Peyronie's disease?. Journal of Clinical Urology, 0, , 205141582210946.	0.1	2